Table 1. Clinicopathologic and treatment characteristics in patients with germline CDH1 mutation who underwent prophylactic total gastrectomy.

Prophylactic Total Gastrectomy	All patients (n=32) n or median (% or range)	Hand-sewn anastomosis (n=10) n or median (% or range)	Modified Orringer anastomosis (n=22) n or median (% or range)
Age (years)	42 (16-58)	42 (26-50)	42 (16-58)
Gender
Male	10 (31.3)	6 (60.0)	4 (18.2)
Female	22 (68.7)	4 (40.0)	18 (81.8)
Body mass index	25.6 (18.0-41.8)	25.6 (22.1-41.8)	25.8 (18.0-36.3)
Gastrointestinal symptoms at presentationa
Abdominal pain or discomfort	4 (12.5)	3 (30.0)	1 (4.5)
Nausea or vomiting	2 (6.2)	1 (10.0)	1 (4.5)
Dyspepsia or heartburn	2 (6.2)	1 (10.0)	1 (4.5)
Dysphagia	1 (3.1)	0 (0.0)	1 (4.5)
Diarrhea	2 (6.2)	1 (10.0)	1 (4.5)
None	23 (71.9)	5 (50.0)	18 (81.8)
Family history
Gastric cancer	32 (100.0)	10 (100.0)	22 (100.0)
Family members with CDH1 mutation	29 (90.7)	9 (90.0)	20 (90.9)
Breast cancer	12 (37.5)	4 (40.0)	8 (36.4)
Operative time (minutes)	190 (124-308)	229 (187-308)	167 (124-267)
Estimated intraoperative blood loss (milliliters)	100 (50-1000)	300 (100-800)	100 (50-1000)
Length of stay (days)	8 (7-12)	7 (7-8)	8 (7-12)
Anastomotic leak	0 (0.0)	0 (0.0)	0 (0.0)
Anastomotic stricture	1 (3.1)	1 (10.0)	0 (0.0)
30-day morbidity	3 (9.4)	1 (10.0)	2 (9.1)
30-day mortality	0 (0.0)	0 (0.0)	0 (0.0)
Weight loss (nadir % from baseline)	15.8 (0.6-43.2)	15.7 (8.9-43.2)	16.0 (0.7-28.8)
Presence of microscopic foci of carcinoma
Noninvasive (intramucosal or in situ)	9 (28.2)	7 (70.0)	2 (9.1)
Invasive (≥T1a)	19 (59.4)	1 (10.0)	18 (81.8)
Noninvasive and Invasive	2 (6.2)	1 (10.0)	1 (4.5)
None	2 (6.2)	1 (10.0)	1 (4.5)
Lymph nodes resected (n)	13 (1-40)	13 (6-18)	13 (1-40)

^aSymptoms not mutually exclusive